Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment- naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial

被引：1
|
作者：
Procopio, Giuseppe
Verzoni, Elena
Bracarda, Sergio
Ricci, Sergio
Ridolfi, Laura
Sacco, Cosimo
Miceli, Rosalba
Porta, Camillo
Bregni, Marco
Bajetta, Emilio
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Osped San Donato, Dept Oncol, USL 8, Arezzo, Italy
[3] Osped Santa Chiara, Pisa, Italy
[4] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[5] Univ Hosp Udine, Udine, Italy
[6] Univ San Matteo, Fdn IRCCS Policlin, Pavia, Italy
[7] Osped Busto Arsizio, Busto Arsizio, Italy
[8] Policlin Monza, Ist Oncol, Monza, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.356
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Sacco, C.
    Ridolfi, L.
    Porta, C.
    Miceli, R.
    Zilembo, N.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 2967 - 2971
  • [2] Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial
    Verzoni, Elena
    Bracarda, Sergio
    Ricci, Sergio
    Sacco, Cosimo
    Ridolfi, Laura
    Porta, Camillo
    Miceli, Rosalba
    Zilembo, Nicoletta
    Bajetta, Emilio
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Sacco, C.
    Ridolfi, L.
    Porta, C.
    Miceli, R.
    Zilembo, N.
    Bajetta, E.
    BRITISH JOURNAL OF CANCER, 2011, 104 (08) : 1256 - 1261
  • [4] Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
    G Procopio
    E Verzoni
    S Bracarda
    S Ricci
    C Sacco
    L Ridolfi
    C Porta
    R Miceli
    N Zilembo
    E Bajetta
    British Journal of Cancer, 2011, 104 : 1256 - 1261
  • [5] Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Sacco, C.
    Ridolfi, L.
    Porta, C.
    Miceli, R.
    Zilembo, N.
    Bajetta, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Miceli, R.
    Bertolini, A.
    Porta, C.
    Ridolfi, R.
    Zilembo, N.
    Bajetta, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 425 - 425
  • [7] A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Sacco, C.
    Ridolfi, L.
    Porta, C.
    Miceli, R.
    Zilembo, N.
    Bajetta, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2).
    Batten, Julia Anne
    Samlowski, Wolfram E.
    Parikh, Kinjal
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Tantravahi, Srinivas Kiran
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).
    Stenehjem, David D.
    Toole, Michael
    Merriman, Joseph
    Parikh, Kinjal
    Daignault, Stephanie
    Scarlett, Sarah
    Esper, Peg
    Skinner, Katherine
    Udager, Aaron
    Tantravahi, Srinivas Kiran
    Straubhar, Alli M.
    Agarwal, Archana M.
    Van Atta, Joan
    Grossmann, Kenneth F.
    Samlowski, Wolfram E.
    Redman, Bruce G.
    Agarwal, Neeraj
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)
    Stenehjem, David D.
    Parikh, Kinjal
    Batten, Julia Anne
    Van Atta, Joan
    Crispin, Hilda
    Sageser, Daniel S.
    Grossmann, Kenneth F.
    Wang, Junfeng
    Tantravahi, Srinivas Kiran
    Samlowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345